Drug Trial Radar · NCT07405671
Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
988
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Research Foundation Flanders
- First posted
- Feb 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether the antiarrhythmic drug flecainide can be used as safely as standard rhythm-control drugs in people with atrial fibrillation (AF) and stable coronary artery disease (CAD). The study includes adults aged 18 years and older who have AF and known but stable coronary artery disease. The main questions this study aims to answer are: * Is treatment with flecainide as safe as standard rhythm-control drugs (sotalol or amiodarone) in this patient group? * Does flecainide lead to similar or fewer serious side effects, hospitalisations, or deaths compared with standard treatment? Researchers will compare patients treated with flecainide to patients treated with standard rhythm-control therapy (sotalol or amiodarone) to see whether flecainide is not worse in terms of safety outcomes. Participants will: * Be randomly assigned to receive either flecainide or standard rhythm-control medication * Take the assigned medication as part of routine clinical care * Attend regular follow-up visits at the hospital and have additional follow-up by telephone * Undergo routine heart tests such as electrocardiograms and echocardiography * Complete questionnaires about symptoms, quality of life, and daily functioning This study follows patients for at least one year and collects information on safety, heart rhythm outcomes, quality of life, and healthcare use.
Conditions
- Atrial Fibrillation (AF)
- Coronary Artery Disease
Interventions
flecainideDrug
Flecainide, a class Ic anti-arrhythmic drug Recommended starting dose of 100 to 150 mg per day per os, either spread in 2 equal doses BID or in 1 dose OD with controlled release formulation. Flecainide will always be combined with an AV nodal blocker (beta-blocker or diltiazem/verapamil).
Sotalol or AmiodaroneDrug
Class III anti-arrhythmic drug: Sotalol or amiodarone as per physician preference. Recommended starting doses: * Sotalol: 80 mg BID per os, with a dose adjustment to once daily if the eGFR is between 40 and 60 mL/min. * Amiodarone: loading dose of 600 mg daily per os in divided doses for 1 week, followed by 400 mg daily per os in divided doses for 1 week, and subsequently 200 mg per os once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite safety outcomeTime frame: 1 year
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
AZorg
Aalst, Belgium · Recruiting
Imelda
Bonheiden, Belgium · Not yet recruiting
AZ ST-JAN Brugge A.V.
Bruges, Belgium · Not yet recruiting
Universitair Ziekenhuis Antwerpen
Edegem, Belgium · Recruiting
Ziekenhuis Oost Limburg
Genk, Belgium · Not yet recruiting
Az Maria Middelares Gent
Ghent, Belgium · Not yet recruiting
AZ St.-Elisabeth Herentals VZW
Herentals, Belgium · Not yet recruiting
Jan Yperman Ziekenhuis
Ieper, Belgium · Not yet recruiting
Algemeen Ziekenhuis Groeninge
Kortrijk, Belgium · Not yet recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Algemeen Ziekenhuis Delta
Roeselare, Belgium · Not yet recruiting
AZ Rivierenland
Rumst, Belgium · Not yet recruiting
Vitaz
Sint-Niklaas, Belgium · Not yet recruiting
AZ Turnhout
Turnhout, Belgium · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.